ClinicalTrials.gg
CompletedNCT05445167Updated Nov 25, 2025

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain

A Phase 3 interventional study of KLH-2109 and Placebo in Uterine Fibroids (MeSH Heading: Leiomyoma), sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Leiomyoma with a site in Japan — none open to participants now, none under way, none of them phase 3. Leiomyoma · Japan.

Enrollment
8th of 10
89 · median 185
Started
2022
with 1 other
Phase 3
8 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
2 of 12
Kissei Pharmaceutical Co., Ltd.

Among the 12 studies in Leiomyoma with a site in Japan, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 8 in phase 3, and was the 11th registered.

Leiomyoma

438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

None of the 12 studies in Leiomyoma with a site in Japan is open now. The open studies under Leiomyoma, anywhere →

Who these studies take

Of the 43 Leiomyoma studies recruiting now, 21 (49%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 9 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Leiomyoma with a site in Japan as a file.
02

Study summary

Multi-center, randomized, double-blind, parallel-group study to confirm superiority of KLH-2109 to placebo in uterine fibroids patient with menorrhagia and pain

03

Conditions studied

  • Uterine Fibroids (MeSH Heading: Leiomyoma)

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal Japanese woman diagnosed with uterine fibroids
  • Patients confirmed by transvaginal ultrasonography to have at least 1 myoma that meet all of the following conditions:
  • Larger than a certain standard
  • No calcification
  • Not receiving surgical treatment
  • Patients with a normal menstrual cycle
  • Patients diagnosed with menorrhagia
  • Patients with pain symptoms associated with uterine fibroids

Exclusion criteria

Exclusion Criteria:

  • Patients with complication or history of blood system diseases (salasemia, sickle erythrocyte anemia, folic acid deficiency, coagulation disorder, etc.) (excluding iron deficiency anemia and latent iron deficiency anemia)
  • Patients with lower abdominal pain due to irritable bowel syndrome or lower abdominal pain due to severe interstitial cystitis
  • Patients with undiagnosed abnormal genital bleeding
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    KLH-2109

    Drug: KLH-2109

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Oral administration

  • DrugPlacebo

    Oral administration

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with a total PBAC score of less than 10 from Week 6 to 12 after beginning of study drug administration

    PBAC (pictorial blood loss assessment chart) score

    Time frame: Up to 12 weeks

  2. Proportion of women with a maximum NRS for pain score of 1 or less during 28 days before the end of study drug administration

    NRS (numeric rating scale) for pain

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Proportion of subjects with a total PBAC score of less than 10 from Week 2 to 6 after beginning of study drug administration

    PBAC (pictorial blood loss assessment chart) score

    Time frame: Up to 12 weeks

  2. Proportion of subjects with a total PBAC score of less than 10 during 6 weeks before end of study drug administration

    PBAC (pictorial blood loss assessment chart) score

    Time frame: Up to 12 weeks

  3. Proportion of subjects with a maximum NRS score of 1 or less for pain symptoms every 28 days

    NRS (numerical rating scale)

    Time frame: Up to 12 weeks

  4. Proportion of subjects with maximum NRS score of zero for pain symptoms during 28 days before end of study drug administration

    NRS (numerical rating scale)

    Time frame: Up to 12 weeks

  5. Proportion of subjects with a maximum NRS score of zero for pain symptoms every 28 days

    NRS (numerical rating scale)

    Time frame: Up to 12 weeks

  6. Average NRS score every 28 days for pain symptoms

    NRS (numerical rating scale)

    Time frame: Up to 12 weeks

  7. Percentage of asymptomatic days (number of the days with NRS score of zero for pain symptoms) during 28 days before end of study drug administration

    NRS (numerical rating scale)

    Time frame: Up to 12 weeks

  8. Percentage of asymptomatic days (number of the days with NRS score of zero for pain symptoms) every 28 days

    NRS (numerical rating scale)

    Time frame: Up to 12 weeks

  9. Incidence of adverse events and adverse drug reactions

    Adverse events and adverse drug reactions

    Time frame: Up to 12 weeks

07

Study locations

1 site
  • Clinical Research Site
    Multiple Locations, Japan
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Feb 2024, 16 months.

Of 25 phase 3 interventional studies under Leiomyoma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 41. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jul 6, 2022
StartActual
Oct 11, 2022
Primary completionActual
Feb 16, 2024
CompletionActual
Feb 16, 2024
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05445167
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Oct 11, 2022
Primary completion
Feb 16, 2024
Completion
Feb 16, 2024
Last update
Nov 25, 2025

Study contacts

Yoshitaka Shimizu
study director · Kissei Pharmaceutical Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linzagolix

Start the discussion